Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease

Yamada, Yukiko; Sugita, Sunao; Tanaka, Hiroyuki; Kamoi, Koju; Kawaguchi, Tatsushi; Mochizuki, Manabu

doi:10.1136/bjo.2009.158840

Cited by 115 publications

(64 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…70,71 There have since been multicentred trials in anti-TNF therapy using the chimeric anti-TNF-a mAb infliximab for treatment of Behcet's disease (BD). 72,73 Furthermore, most recently, reports show in favour of infliximab compared with conventional therapy with CsA, 74 and indeed challenges us to think of earlier use of such targeted therapy. Although criticisms can be levied at this trial or other comparators being largely cohort studies, we are now entering the arena of adequately powered commercially driven RCTs, which will provide level I evidence for or against anti-TNF therapy (using humanised anti-TNF agent, Humira), both in JIA-uveitis and in adult uveitis, and these will define future treatment.…”

Section: Recent and Future Treatmentsmentioning

confidence: 99%

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Lee

Dick

2011

Eye

View full text Add to dashboard Cite

The blockbuster drug paradigm is under increasing scrutiny across the biopharmaceutical industry. Intraocular inflammation poses particular challenges to this, given the heterogeneity of conditions in the uveitis spectrum, and the increasing acknowledgement of individual patient and disease variance in underlying immune responses. This need has triggered a drive towards personalised and stratified medicine, supported and enabled as a result of continued development of both experimental models and molecular biological techniques and improved clinical classification. As such we have the ability now to systematically appraise at a genomic, transcriptomic, and proteomic level individual immunophenotype, and the promise that in the eye this can be augmented by in vivo immune imaging to identify individual immunopathology. With such advances all running in parallel, we are entering an era of experimental medicine that will facilitate early diagnosis, generate biomarkers for accurate prognostication, and enable the development of individualised and targeted therapies, which can progress rapidly into clinical practice.

show abstract

Section: Recent and Future Treatmentsmentioning

confidence: 99%

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Lee

Dick

2011

Eye

View full text Add to dashboard Cite

show abstract

“…However, there are an accumulating number of publications reporting successful therapy with inflixamab (monoclonal antibody directed against TNF-α) and other biologics [174,175]. For patients who develop CVT, anticoagulation is required, even in patients with hemorrhagic infarction [176].…”

Section: Behçet's Diseasementioning

confidence: 99%

Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit

Geldern¹,

McPharlin

Becker

2012

Neurotherapeutics

View full text Add to dashboard Cite

This chapter will review the spectrum of immunemediated diseases that affect the nervous system and may result in an admission to the neurological intensive care unit. Immunomodulatory strategies to treat acute exacerbations of neurological diseases caused by aberrant immune responses are discussed, but strategies for long-term immunosuppression are not presented. The recommendations for therapeutic intervention are based on a synthesis of the literature, and include recommendations by the Cochrane Collaborative, the American Academy of Neurology, and other key organizations. References from recent publications are provided for the disorders and therapies in which randomized clinical trials and large evidenced-based reviews do not exist. The chapter concludes with a brief review of the mechanisms of action, dosing, and side effects of commonly used immunosuppressive strategies in the neurocritical care unit.

show abstract

“…Yazarlar infliksimab›n atak say›s›na etkisinin istatistiksel olarak anlaml› derecede daha güçlü oldu¤u-nu ancak görsel kazan›m aç›s›ndan gruplar aras›nda anlaml› bir farkl›l›k olmad›¤›n› bildirmifltir. 27 Baflka bir ça-l›flmada Behçet hastalar›nda ilaç dozu ile klinik etki aras›nda güçlü bir iliflki oldu¤u gösterilmifltir. 28 Behçet hastal›¤›nda ajan›n intraoküler inflamasyonu kontrol etmesi yan›nda hastal›¤›n nörolojik eklem, barsak ve genital tutulum gibi farkl› dokulardaki bulgular›n› kontrol etmede baflar›l› oldu¤u gösterilmifltir.…”

Section: Tnf Antagonistleriunclassified

New Treatment Alternatives in the Management of Non-İnfectious İntraocular İnflammations: Biologic Agents

Emre¹,

Tutkun²

2011

tjo

View full text Add to dashboard Cite

ÖzetEnfeksiyöz olmayan üveitlerin tedavisinde son y›llara kadar genel olarak immün sistemi bask›layan ilaçlar kullan›lmak-tayd›. Ancak gen mühendisli¤indeki geliflmeler, inflamatuar süreçte yer alan özgün molekülleri hedefleyen proteinlerin sentezini ve bu proteinlerin terapötik olarak kullan›lmalar›n› mümkün k›lm›flt›r. Genel olarak protein yap›s›ndaki bu ajanlar biyolojik ajanlar olarak adland›r›lm›fllard›r. Oftalmologlar›n biyolojik ajanlar ile tecrübeleri s›n›rl› olsa da, bu ajanlar romatoloji ve dermatoloji baflta olmak üzere di¤er disiplinler taraf›ndan yo¤un biçimde kullan›lmaktad›rlar. ‹nterferon, infliksimab ve adalimumab baflta olmak üzere birçok biyolojik ajan›n üveit hastalar›nda kullan›m› ile ilgili literatür verisi olmas›na ra¤men henüz bu endikasyonda ruhsatl› kullan›mlar› yoktur. Ayr›ca bu ajanlar›n kullan›m› s›ras›nda dikkat edilmesi gereken güvenlik önlemleri ve önemli risk faktörleri mevcuttur. Bu derlemenin amac›, dirençli üveit hastalar›nda kullan›labilen biyolojik ajanlar konusunda güncel ve kapsaml› bilgi sunmakt›r. ( SummaryConventional immunosuppressive agents have been traditionally used for the treatment of noninfectious uveitis. Recent developments in genetic engineering have made it possible to synthesize proteins that target specific molecules playing role in the inflammatory response. These agents are generally in protein structure and are named biologic agents. While there is limited experience with biologics in the field of ophthalmology, they are commonly used in other disciplines such as rheumatology and dermatology. Although considerable data have accumulated in the uveitis literature regarding the use of biologic agents, including mainly interferon, infliximab, and adalimumab, their use for this indication is still off-label. Moreover, there are certain precautions that have to be taken into account, as well as important safety issues associated with their use. The purpose of this paper is to present an updated comprehensive review of biologic agents that may be used for the treatment of refractory uveitis. (Turk J Ophthalmol 2011; 41: 243-55 GiriflEnfeksiyöz olmayan üveitlerin tedavisinde kullan›lmakta olan immunsupresan ajanlar, ba¤›fl›kl›k sistemini genel olarak bask›lamakta veya sapt›rmaktad›rlar. Bu tedavi yöntem-lerinin sebep olduklar› ciddi yan etkiler ile tedaviye dirençli olgular, hekimleri yeni tedavi aray›fllar›na itmektedir. Son y›llarda araflt›r›lan biyolojik ajanlar, inflamatuar süreçteki öz-gün molekülleri (proteinleri) etkileyerek ba¤›fl›kl›k sisteminde daha s›n›rl› ancak etkin bir tedavi sa¤lamaktad›rlar. Biyolojik ajanlar, moleküler rekombinant DNA teknolojisi kullan›larak elde edilen proteinlerdir. Bu ajanlar›n büyük ço¤un-lu¤u monoklonal antikorlard›r. fiu an için enfeksiyöz olmayan üveitlerin tedavisinde bafll›ca kullan›lan biyolojik ajanlar 3 grupta s›n›fland›r›labilir; i. Interferon-α, ii. TNF-α antagonistleri ve iii. Çeflitli sitokin veya yüzey membran proteini gibi farkl› hedeflere yönelik antikorlar veya füzyon proteinleri.

show abstract

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease

Abstract: During the initial 6 months of treatment, infliximab proved to be more effective in reducing acute episodes of uveitis in Behçet disease.

Cited by 115 publications

References 11 publications

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit

New Treatment Alternatives in the Management of Non-İnfectious İntraocular İnflammations: Biologic Agents

Contact Info

Product

Resources

About